The Serine/Threonine Protein Kinase mTOR pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase mTOR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase mTOR pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, Respiratory, and Immunology which include the indications Solid Tumor, Ovarian Cancer, Epilepsy, Parkinson’s Disease, Idiopathic Pulmonary Fibrosis, Viral Respiratory Tract Infection, Immunology, and Autoimmune Disorders. It also reviews key players involved in Serine/Threonine Protein Kinase mTOR targeted therapeutics development with respective active and dormant or discontinued products.
The Serine/Threonine Protein Kinase mTOR pipeline targets constitutes close to 83 molecules. Out of which, approximately 74 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 4, 18, 10, 1, 37, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 8, and 1 molecule.
Serine/Threonine Protein Kinase mTOR overview
Serine/Threonine Protein Kinase mTOR is a crucial protein kinase that regulates cellular processes like growth, proliferation, motility, survival, protein synthesis, autophagy, and transcription. It is a central component of two distinct multiprotein complexes known as mTORC1 and mTORC2. These complexes play distinct biological functions by directly phosphorylating different substrates and indirectly controlling other effectors.
For a complete picture of Serine/Threonine Protein Kinase mTOR’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
